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ABSTRACT
PD-L1 is expressed by a subset of patients with metastatic melanoma (MM) with 
an unfavorable outcome. Its expression is increased in cells resistant to BRAF or MEK 
inhibitors (BRAFi or MEKi). However, the function and regulation of expression of PD-
L1 remain incompletely understood.
After generating BRAFi- and MEKi-resistant cell lines, we observed marked up-
regulation of PD-L1 expression. These cells were characterized by a common gene 
expression profile with up-regulation of genes involved in cell movement. Consistently, 
in vitro they showed significantly increased invasive properties. This phenotype was 
controlled in part by PD-L1, as determined after silencing the molecule. Up-regulation 
of PD-L1 was due to post-transcriptional events controlled by miR-17-5p, which 
showed an inverse correlation with PD-L1 mRNA. Direct binding between miR-17-5p 
and the 3’-UTR of PD-L1 mRNA was demonstrated using luciferase reporter assays.
In a cohort of 80 BRAF-mutated MM patients treated with BRAFi or MEKi, 
constitutive expression of PD-L1 in the absence of immune infiltrate, defined the 
patient subset with the worst prognosis. Furthermore, PD-L1 expression increased in 
tissue biopsies after the metastatic lesions became resistant to BRAFi or MEKi. Lastly, 
plasmatic miR-17-5p levels were higher in patients with PD-L1+ than PD-L1- lesions.
In conclusion, our findings indicate that PD-L1 expression induces a more 
aggressive behavior in melanoma cells. We also show that PD-L1 up-regulation in 
BRAFi or MEKi-resistant cells is partly due to post-transcriptional mechanisms that 
involve miR-17-5p, suggesting that miR-17-5p may be used as a marker of PD-L1 
expression by metastatic lesions and ultimately a predictor of responses to BRAFi or 
MEKi.
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INTRODUCTION
The therapy of metastatic melanoma (MM) was 
radically changed by the introduction of inhibitors of the 
BRAF oncogene, which is mutated in ≈40-50% of patients. 
The BRAF inhibitors (BRAFi) vemurafenib and dabrafenib 
were proved to be more successful than conventional 
chemotherapy in the treatment of these patients in terms 
of activity and efficacy, achieving partial and complete 
remissions in many instances [1, 2]. However, resistance 
to BRAFi typically emerges a few months after beginning 
of therapy [3]. Following prolonged treatment with 
BRAFi, some patients also develop secondary tumors [4]. 
Both these phenomena are attributed to the paradoxical 
activation of MEK/ERK signaling consequent to the 
upstream block induced by BRAFi [5]. This finding 
was the rationale for the introduction of MEK inhibitors 
(MEKi) in the management of these patients [6]. The 
combination of BRAFi with MEKi was proposed as a 
strategy to delay or even prevent the onset of resistance, 
without increasing the risk of developing secondary 
cancers. Three large, prospective, randomized clinical 
trials indicate that combined therapy is significantly more 
effective than either drug used alone and that resistance 
occurs at a later stage, proposing this combination as the 
new standard treatment for this subset of MM patients 
[7–9].
The alternative or complementary therapeutic strategy 
for patients with MM is to restore immune functions, 
boosting T cell specific responses against the tumor 
[10]. Among the immune checkpoint targets of clinical 
importance is PD-1, which is expressed by exhausted T 
lymphocytes [11]. PD-1 binds to the PD-L1 ligand, which 
may be expressed by tumor cells, including melanoma 
[12, 13]. Recent clinical trials with anti-PD-1 antibodies 
(nivolumab and pembrolizumab) have demonstrated higher 
objective response rates and increased overall survival 
compared to chemotherapy [14–16], albeit at the cost of 
significant immune-related toxicities, particularly when 
used in combination with anti-CTLA-4 antibodies [17, 18].
Regulation of PD-L1 expression by melanoma is 
an area of intense investigation. On the one side, PD-
L1 expression is induced by interferon-gamma, in turn 
produced by activated CD8+ T lymphocytes, highlighting 
immune escape mechanisms [19–22]. On the other side, 
PD-L1 may be induced after paradoxical activation of the 
MAP kinases, as recently shown [23, 24]. Furthermore, 
PTEN loss was found to up-regulate PD-L1, likely through 
the over-activation of the PI3K/Akt pathway, at least in 
other tumor models [25, 26].
In our previous work, we showed that out of a 
panel of 12 melanoma cell lines, A375 was the only one 
carrying mutations in the BRAF oncogene where a distinct 
population of PD-L1+ cells could be defined. The sorted 
PD-L1+ subset of the A375 cell line was characterized by 
a highly invasive phenotype, with an enhanced ability to 
grow in xenograft models. This phenotype was attributed 
to the transcriptional modulation of a set of genes involved 
in adhesion and migration [27].
In the present work we directly link expression 
of PD-L1 to a more aggressive behavior of melanoma 
cell lines. This finding is substantiated by data obtained 
in patients, where intrinsic PD-L1 expression defines a 
subset of patients with the most unfavorable prognosis. 
Furthermore, we define a novel post-transcriptional circuit 
responsible for PD-L1 up-regulation in BRAFi-resistant 
melanoma cells, which is based on the direct interaction 
between the 3’-UTR mRNA of PD-L1 and miR-17-5p. 
Lastly, we show that miR-17-5p levels in patients with 
metastatic melanoma inversely correlate with PD-L1 
expression and may predict sensitivity to BRAFi.
RESULTS
Resistance to BRAFi and MEKi is accompanied 
by induction of PD-L1 expression in BRAFV600E-
mutated melanoma cell lines
The BRAFV600E mutated A375 (20% of cells 
constitutively expressing PD-L1), SKMEL5 and M14 
(both PD-L1-, Figure 1A) cell lines were rendered resistant 
to BRAFi or MEKi by repeated exposure to increasing 
concentrations of each drug. Resistant cells are indicated 
as BiR and MiR, respectively. Doses were slowly escalated 
over a period of 12 weeks to reach a plateau of 1.6 μM 
for both drugs. Resistance to BRAFi or MEKi was 
confirmed using the MTT assay (Figure 1B), as well as in 
xenograft models where A375/BiR, the cell line selected 
for in vivo experiments, failed to respond to treatment 
with dabrafenib, at variance with control cells (Figure 
1C). No double-resistant cell line could be stabilized, at 
least under these experimental conditions. In these cell 
lines, resistance to BRAFi and MEKi was accompanied 
by paradoxical activation of ERK1/2 tyrosine kinase and 
STAT3 downstream activation (Figure 1D).
MiR cell lines were characterized by a robust 
up-modulation of CD274/PD-L1, both at the mRNA 
and protein levels (Figure 2A-2C). Among BiR lines, 
expression of PD-L1 increased in A375 (from 20% to 
100%) and SKMEL5 (from 0% to 100%), while M14 
remained PD-L1- (Figure 2A-2C). Confocal microscopy 
and flow cytometry analyses confirmed that PD-L1 was 
intensely expressed at the cell surface (Figure 2A-2C and 
Figure 1A).
BRAFi- and MEKi-resistant cell lines show a 
distinct gene profile, which partially overlaps 
with that of A375/PD-L1+ cells
We previously reported that the PD-L1+ variant 
of the A375 cell line is characterized by a specific gene 
expression profile [27]. We now compared the genetic 
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Figure 1: Establishment and characterization of BRAFV600E-mutated melanoma cell lines resistant to BRAFi and 
MEKi. A. Flow-cytometric histogram plots reporting surface expression of PD-L1 by A375, A375/PD-L1+, SKMEL5, M14 cell lines, 
before (S cells) and after the acquisition of resistance to BRAFi (BiR) and MEKi (MiR). The bars within the histogram plot define the 
positive cut-off. B. Cell growth of A375, SKMEL5 and M14 melanoma cell lines sensitive (black line) or resistant (red line) to BRAFi 
(Dabrafenib) or MEKi (Pimasertib) used at scalar doses for 72 hours as measured by MTT assay. Data are represented as % of control 
(untreated cells). Data from 3 independent experiments, each performed in triplicate. C. Box plot showing tumor weight (g) of A375/S 
or /BiR cells after subcutaneous injection of 107 cells in matrigel in NOD/SCID mice (n=5). Cells were left to grow for 14 days before 
beginning treatment with BRAFi (30 mg/kg/daily gavage) for 1 week. Mice were then sacrificed and lesions stained for MIB1 to determine 
the proliferative fraction (representative images are shown). Original magnification x2.5 (left panels), scale bar 50 μm. D. Western blot 
analysis of p-ERK1/2 and pSTAT3, and the corresponding total protein of A375 and SKMEL5 S, BiR and MiR. S: sensitive, BiR: BRAFi 
resistant, MiR: MEKi resistant.
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signature of A375/BiR to that of A375/PD-L1+ cells 
and found 206 commonly modulated genes (Figure 
3A and Supplementary Table 1). Among them, the 
most significantly up-modulated genes pertained to the 
“adhesion”, “movement” and “cell growth” categories, 
while “antigen presentation” was the most significantly 
down-modulated gene category. This signature suggests 
that cell movement and immune escape are mechanisms 
shared between the A375/PD-L1+ and the A375/BiR 
variants (Figure 3A). We then compared the RNA 
sequencing profiles of A375/BiR and /MiR and those 
of SKMEL5/BiR and /MiR and identified 852 genes 
that were similarly modulated in the four line variants 
(Supplementary Table 2). Among these genes, 574 (67%) 
were up-regulated and 278 (33%) were down-regulated 
(Figure 3B). CD274 (PD-L1) was among the most 
significantly overexpressed genes in the BiR and MiR 
variants, confirming the validity of the approach (Figure 
3C). Gene ontology (GO) analysis confirmed that the main 
biological processes modulated during the acquisition 
of resistance concerned cell movement and immune 
responses (Figure 3D). Specifically, genes involved in cell 
adhesion, movement, signaling and immune/inflammatory 
responses were significantly up-regulated, while genes 
Figure 2: BRAF or MEK inhibitors resistance is accompanied by PD-L1 overexpression. A-C. Expression of CD274/PD-L1 
at the mRNA (left graph) and protein levels, analyzed as Mean Fluorescence Intensity (MFI, middle graph) in A375 A., SKMEL5 B. and 
M14 C. melanoma cell lines. Surface expression was confirmed by confocal microscopy analysis. Original magnification x63.
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Figure 3: PD-L1+ BRAFi or MEKi-resistant melanoma cells are characterized by a distinct genetic profile. A. Venn 
diagram showing genes commonly modulated when comparing A375/BiR cells to the A375/PD-L1+ clone. The histograms represent 
enriched gene categories obtained after analyzing the 206 common genes. B. Venn diagrams showing 852 common differentially expressed 
genes in BiR and MiR A375 and SKMEL5 cell lines obtained by RNAseq analysis. C. Most representative up-regulated (red) and down-
regulated (green) differentially expressed genes belong to the common 852 genes. D. Histograms represent the more enriched GO categories 
in the resistant variants. E. Differential expression of integrin-α3 (ITGα3), CD24 and NCAM1 (CD56) protein of sensitive and BRAFi or 
MEKi-resistant melanoma cells by FACS analysis.
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involved in antigen processing and presentation and 
cell morphogenesis were down-regulated (Figure 3C-
3D). Among these genes, we confirmed up-regulation of 
integrin α3 (ITGα3), CD24 and NCAM1 (CD56) at the 
protein level (Figure 3E), which have been previously 
connected to increased aggressiveness of melanoma cells. 
Specifically, ITGα3 is expressed by melanoma cells with 
a highly invasive potential [28], CD24 is considered a 
negative prognostic factor for patients with cutaneous 
melanoma [29], while CD56 is a neural marker, which can 
be expressed by melanomas with desmoplastic and spindle 
cell differentiation [30].
Over-expression of PD-L1 in BRAFi- and MEKi-
resistant cell lines contributes to increased 
invasiveness
Following the gene expression profiles, we 
hypothesized that BiR and MiR cells would show a more 
aggressive behavior when compared to the drug-sensitive 
counterparts. Increased motility and aggressiveness of 
A375/PD-L1+ cells compared to A375/PD-L1- cells was 
previously confirmed both in vitro and in vivo [27]. We 
now extended these studies to A375 and SKMEL5 /
BiR and /MiR, by analyzing their ability to repair 
wounds. Wound-healing assays performed at 48 hours 
clearly demonstrated that both /BiR and /MiR A375 and 
SKMEL5 cells repaired the wound in a more efficient 
way than the sensitive (S) counterpart (Figure 4A-4B). 
A375 cells showed a mean % of repair of 21±2.5% vs 
73±4% of A375/BiR vs 69±3% of A375/MiR (Figure 
4A-4B). SKMEL5 cells showed a mean of % of repair 
of 15±2.5% vs 69±4% of SKMEL5/BiR vs 60±9% of 
SKMEL5/MiR (Figure 4A-4B). Likewise BiR and MiR 
cells showed significantly increased chemotactic and 
invasive performances as compared to the S counterparts 
(Figure 4C-4D and Supplementary Figure 1). Invasion 
index for A375 was 3.5±5 SD vs 193±51 SD of A375/
BiR and 197±48 SD of A375/MiR. Invasion index for 
SKMEL5 was 1.7±3 SD vs 226±53 SD for SKMEL5/BiR 
and 213±50 SD for SKMEL5/MiR (Figure 4C).
These results indicate that cells that constitutively 
express PD-L1 and cells that acquire PD-L1 as a 
consequence of the BiR state show modulation of common 
genes and acquire similar behavioral patterns.
Silencing of PD-L1 expression influences 
aggressiveness
We then asked whether PD-L1 was directly involved 
in determining this phenotype. To answer this question, 
A375/BiR or /MiR and SKMEL5/BiR or /MiR cells were 
infected with a lentivirus carrying a PD-L1-specific (sh) 
or a control shRNA (CTLR). Cells were then repeatedly 
selected by cloning and sorting resulting in different 
clones with a marked decrease in PD-L1 surface levels, as 
determined by flow cytometry and western blot analysis in 
all cell line variants (Figure 5A-5B). Silencing of PD-L1 
significantly decreased the ability of A375/BiR and /MiR 
and of SKMEL5/BiR and /MiR cells to repair a wound 
(Figure 5C-5D). A375/BiR CTRL cells showed a mean 
% of repair of 77±9% vs 44±4% of A375/BiR sh, A375/
MiR CTRL 76±6% vs 32±6% of A375/MiR sh (Figure 
5C-5D). SKMEL5/BiR CTRL cells showed a mean of 
% of repair of 83±9% vs 62±11% of SKMEL5/BiR sh, 
SKMEL5/MiR CTRL 66±6% vs 37±6% of SKMEL5/MiR 
sh (Figure 5C-5D). Furthermore, silencing of PD-L1 in 
resistant cells markedly reduced the expression of CD56, 
and – to a lesser extent – of ITGα3 (Figure 5E), linking 
PD-L1 expression to the activation of a genetic program 
dictating a more aggressive phenotype, characterized by 
increased motility and invasion.
miR-17-5p post-transcriptionally regulates PD-
L1 expression
These findings underline the importance of 
understanding the molecular mechanisms behind PD-
L1 up-regulation in BiR or MiR melanoma cell lines. 
Previous investigators showed that PD-L1 up-regulation is 
dependent upon the activation of the JAK/STAT signaling 
pathways, in turn controlled by the MAPK pathway [23]. 
Consistently, BiR and MiR cell lines showed significant 
up-regulation of these signaling pathways (Figure 1D). 
However, exposure to the specific STAT3 inhibitor 
caused only a moderate decrease in PD-L1 expression, 
suggesting that other mechanisms are causing its up-
regulation in resistant cells [23]. For this reason, we asked 
whether PD-L1 up-regulation could be attributed, at least 
partially, to post-transcriptional mechanisms, such as those 
regulated by microRNAs. Based on computer predictions 
(TargetScan 6.0) three microRNAs, namely miR-17-5p, 
miR-155-5p and miR-425-5p were the only three miRs 
potentially targeting CD274/PD-L1 mRNA. However, 
only miR-17-5p showed an inverse correlation with 
CD274/PD-L1 mRNA levels in A375, SKMEL5 and M14 
cell lines. Specifically, miR-17-5p was down-modulated in 
A375 and SKMEL5 /BiR and /MiR variants, as well as in 
M14/MiR cells (Figure 6A). No significant modulation of 
miR-17-5p was observed in M14/BiR cells, where PD-L1 
expression was unaffected (Figure 6A). Consistently, the 
A375/PD-L1+ variant displayed significantly lower miR-
17-5p levels than the PD-L1- counterpart (Figure 6A). 
On the contrary, miR-155-5p and miR-425-5p did not 
shown any apparent modulation in BiR or MiR cell lines 
(Supplementary Figure 2A-2B). Pearson’s correlation 
between CD274/PD-L1 mRNA and miR-17-5p levels 
was r=-0.82, with the A375/BiR and /MiR cells clustering 
together. Similar results were obtained with the SKMEL5 
cells, with r=-0.62. M14 cells behaved differently, with /
BiR cells clustering with the sensitive cells, while M14/
MiR appeared to express high levels of CD274/PD-L1 
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mRNA and low levels of miR-17-5p, with r=-0.87. This 
correlation was confirmed when studying miR-17-5p 
levels in A375/PD-L1+ and A375/PD-L1- constitutive 
variants, with r=-0.80 (Figure 6B).
Transient transfection of pre-miR-17-5p in A375 
and SKMEL5 /BiR and /MiR cell lines was followed by 
a sharp increase in intracellular miR17-5p levels, while 
at the same time CD274/PD-L1 mRNA levels decreased 
(Supplementary Figure 3A and Figure 6C). As expected, 
the drop in mRNA levels was accompanied by decreased 
in protein expression, as determined by western blot 
(Figure 6D) and by flow cytometry (Supplementary 
Figure 3B).
To determine whether miR-17-5p directly binds to 
the 3’-UTR region of PD-L1 we cloned part of 3’-UTR 
of PDL1 and expressed it in a luciferase reporter vector. 
We then co-transfected the reporter vector and miR-17-5p 
in 293T cells and observed a decrease in the luciferase 
Figure 4: Over-expression of PD-L1 in BRAFi- and MEKi-resistant cell lines contributes to increased invasiveness. 
A. Box plots showing % of repair in A375 and SKMEL5 variants, determined by measuring wound area ratio between two time points at 
24 hours and t=0. B. Representative pictures (x10 magnification, scale bar 200 μm) of wound-healing assay comparing S, BiR and MiR 
variants. C. Box plots representing cumulative data of invasion assays performed using A375 and SKMEL5 cell variants. D. Representative 
images (x10 magnification) of A375 (left panels) and SKMEL5 (right panels) cell lines comparing S, BiR and MiR variants.
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Figure 5: PD-L1 silencing influences aggressiveness. A. PD-L1 protein level of silenced infected cells (sh) in comparison to the 
infected control (CTRL) in A375/BiR, A375/MiR, SKMEL5/BiR and SKMEL5/MiR cells. B. Flow-cytometric histogram plots of PD-L1-
silenced A375 and SKMEL5 resistant cell lines. C. Box plot of wound healing repair of A375/BiR, A375/MiR, SKMEL5/BiR, SKMEL5/
MiR CTRL vs sh. D. Representative pictures (x10 magnification, scale bar 200 μm) of wound-healing assay comparing the infected control 
(CTRL) versus the infected (sh) in A375/BiR, A375/MiR and SKMEL5/BiR and SKMEL5/MiR cells. E. Histogram representing CD56 
and ITGα3 surface protein expression in CTRL and sh A375/BiR and SKMEL5/BiR cells.
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Figure 6: miR-17-5p regulates CD274/PD-L1 expression. A. miR-17-5p basal expression in the sensitive (S) and BiR or MiR 
melanoma cells in A375, SKMEL5, M14 and A375/PD-L1+. B. Pearson’s correlation of miR-17-5p and PD-L1 level expression in the 
sensitive (S) and BiR or MiR melanoma cells in A375, SKMEL5, M14 and A375/PD-L1+. C. Relative expression of CD274/PD-L1 in 
miR-17-5p transfected cells in comparison to miR-negative transfected control in A375 and SKMEL5 cell line variants. D. Representative 
blot for PD-L1 protein of BiR or MiR of A375 and SKMEL5 transfected cells with pre-miR-17-5p (indicated as 17) and negative control 
(indicated as neg). E. Relative luciferase activity of 293T cells transfected with miR-17-5p (indicated as 17) or negative control (indicated 
as neg) together with the luciferase vector containing PD-L1 3’-UTR wild type (WT) or mutagenized (MUT). F. Seeding sites of miR-17-5p 
in PD-L1 3’-UTR wild type and mutagenized (MUT).
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activity after 48 hours, suggesting a direct effect (Figure 
6E). Mutagenesis of miR-17-5p binding site in the 3’-UTR 
of PD-L1 mRNA (Figure 6F) failed to modulate luciferase 
activity, confirming specificity of binding between miR-
17-5p and the 3’-UTR of PD-L1 mRNA (Figure 6E).
In agreement with results obtained after silencing 
PD-L1, transfection of miR-17-5p in BiR and MiR 
melanoma cells was followed by a markedly decreased 
ability to repair wounds, indirectly validating the role 
of PD-L1 in this process (Figure 7A-7B). In these 
experimental conditions, miR17-5p levels rose sharply 
upon transfection (Supplementary Figure 3A).
Expression of PD-L1 is acquired by BRAFi-
resistant melanoma lesions, is associated to 
aggressive behavior and unfavorable outcome 
and is inversely correlated with plasmatic miR-
17-5p levels
To obtain an independent validation of our in vitro 
data, we took advantage of a cohort of 80 BRAFV600E-
mutated MM patients, treated with BRAFi. Patient 
characteristics are reported in Supplementary Table 3. 
For each of these patients PD-L1 expression, as well as 
Figure 7: Modulation of PD-L1 can alter the functional properties of tumor cells. A. Quantification as percentage of repair 
of wound-healing assay comparing miR-negative transfected control and miR-17-5p transfected A375/BiR, A375/MiR, SKMEL5/BiR and 
SKMEL5/MiR. B. Representative pictures (x10 magnification, scale bar 200 μm) of A375/BiR, A375/MiR, SKMEL5/BiR and SKMEL5/
MiR.
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tumor infiltration by mononuclear cells (TIMC), were 
determined by immunohistochemistry. Data are available 
for 78 patients, because one PD-L1+ patient was not 
evaluable for TIMC and one patient without TIMC was 
not evaluable for PD-L1 expression.
Four different patient subsets were defined based 
on the combination of the two parameters. Of the 28/78 
patients with a PD-L1+ biopsy, 15 showed evidence of 
TIMC, suggesting that environmental factors, such as 
IFNγ produced by activated T cells, could be responsible 
for PD-L1 expression by the tumor cells. On the contrary, 
13/28 of PD-L1+ patients did not show TIMC, arguing in 
favor of a constitutive expression of PD-L1 in this subset. 
Of the 50/78 patients with a PD-L1- biopsy 14/50 had 
TIMC, while 36/50 did not have TIMC.
Our previous analysis of this cohort indicated that 
expression of PD-L1 by tumor cells and TIMC were two 
independent predictors of response to therapy with BRAFi 
[27, 31]. We now updated results with a median follow-
up of 27.4 months, by which time 45 (64%) patients had 
progressed and 46 (52.5%) had died. Overall, 55 (69%) 
patients had either progressed or died, while 49 (61.3%) 
patients reached a complete or partial response at one time 
during the course of their illness.
Multivariate analysis indicated that patients with a 
PD-L1+ biopsy and without TIMC were the least likely 
to respond to treatment and consequently those with the 
shortest overall survival. This finding is in line with the 
hypothesis that constitutive PD-L1 expression by the 
tumor identifies a subset of MM patients characterized by 
a highly aggressive disease. Patients with PD-L1− biopsies 
and without TIMC (OR 15.69, 95% CI 2.10–117.26, P < 
0.0073) or patients with PD-L1− biopsies, but with TIMC 
(OR 17.26, 95% CI 3.1–96.18, P < 0.0012) showed a 
higher probability to have a complete or partial response 
compared to patients with PD-L1+ biopsies and without 
TIMC, while patients with PD-L1+ biopsies and with 
TIMC showed an intermediate behavior (Figure 8A and 
Supplementary Table 4). Furthermore, after adjusting for 
stage and performance status, lack of PD-L1 expression 
and presence of TIMC were associated to a significantly 
longer progression free survival (PFS, HR 0.37, 95% CI 
0.17–0.84, P < 0.02, Supplementary Table 5) and overall 
survival (OS, HR 0.35 95% CI 0.15–0.84, P < 0.02, 
Supplementary Table 6), compared to patients expressing 
PD-L1 and lacking TIMC. Kaplan Meier curves for PFS 
and OS are shown in Figure 8A and Supplementary 
Figure 4.
In order to evaluate whether PD-L1 could be 
dynamically modulated during BRAFi treatment, we 
obtained paired biopsies before beginning of therapy 
and after the onset of resistance to BRAFi (dabrafenib or 
vemurafenib) from 11 patients. Out of these 11 patients, in 
7 cases (63%, 95% CI 39-94) we observed up-regulation 
of PD-L1 in melanoma cells by immunohistochemistry, 
as shown in three representative patients (Figure 8B-8C). 
Specifically, in 4 cases with PD-L1- pre-treatment biopsies 
(failing to reach the ≥5% threshold) upon resistance we 
observed a shift from PD-L1- to PD-L1+ status, while 
in the remaining cases PD-L1 was highly up-regulated 
in resistant melanoma tissues when compared with 
baseline, with diffuse and uniform membranous pattern of 
expression, irrespective from the presence of infiltrating 
immune cells (Figure 8B-8C and Supplementary Table 7).
Interestingly, we were able to obtain paired biopsies 
in 4 patients who previously received a BRAF inhibitor 
monotherapy (dabrafenib) alone, and subsequently a 
combination of dabrafenib and trametinib. In these 
patients, who progressed during BRAFi and MEKi, we 
did not observe any modulation of PD-L1 expression (not 
shown), in agreement with previous data [32].
Lastly, we asked whether miR-17-5p levels in 
plasma from patients with metastatic melanoma could be 
used as an inverse marker of the expression of PD-L1 by 
the tumor. We collected sera from patients with metastatic 
melanoma before treatment with BRAFi. Patients were 
divided into two groups according to PD-L1 expression 
obtained by IHC: following this approach 16 patients were 
PD-L1+ and 6 PD-L1-. RT-PCR was used to quantify miR-
17-5p levels in patient sera, showing that patients with a 
PD-L1+ tumor had lower levels of miR17-5p (mean±SD 
34.1±3.4), compared to patients with a PD-L1- lesion 
(mean±SD 21.47±2.0, Figure 8D).
DISCUSSION
The therapy of melanoma changed radically with 
the identification of recurrent mutations in genes coding 
for members of the MAPK pathway, which then led to 
the design of targeted inhibitors for both BRAF and MEK 
tyrosine kinases. Resistance to these drugs is a common 
event that is linked to the paradoxical activation of the 
MAP kinases axis, representing the limiting factor in this 
therapeutic approach. More recent studies are showing 
that the combination of tyrosine kinase inhibitors with 
immune checkpoint inhibitors, such as PD-L1, obtains 
more durable responses [33]. The rationale for these 
combinations is that MM frequently express PD-L1, which 
may be transcriptionally regulated by different signals. 
PD-L1 expression is dynamically modulated by IFN-γ, 
produced by infiltrating CD8+ activated T lymphocytes, 
representing an immune escape circuit. However, PD-L1 
may be also expressed by melanoma cells in the absence 
of immune infiltrate, suggesting that expression relies on 
cell autonomous mechanisms.
The aim of this work was twofold. First, we wanted 
to expand our previous observations indicating that PD-
L1 is a marker for an aggressive form of melanoma by 
addressing the issue of whether the molecule may be 
directly involved in determining this phenotype. Secondly, 
we wanted to understand how PD-L1 expression is 
regulated in these cells. The data obtained in vitro were 
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Figure 8: PD-L1 immunohistochemical expression in paired tissue biopsies taken before and after onset of resistance 
in patients treated with BRAF inhibitors (dabrafenib or vemurafenib). A. Survival curves estimated with the Kaplan-Meier 
method, on y axis is indicated the overall survival OV, on the x axis is indicated the time to event in months. B. PD-L1 expression in three 
representative patients (pre-therapy and upon resistance acquisition conditions): patient #15 (vemurafenib): PD-L1 is not expressed before 
resistance while it is observed in 6% of tumor cells after resistance; patient #7 (dabrafenib): PD-L1 positivity in 5% of tumor cells before 
resistance and in 10% of tumor cells upon resistance; patient #8 (dabrafenib): tumor tissue before resistance is considered PD-L1-, being 
observed only in 1% of tumor cells (cut-off ≥5%), while PD-L1 is strongly and diffusely expressed in 80% of tumor cells upon resistance. 
Original magnification x40, scale bar 50 μm. C. Percentage of PD-L1 immunostaining in tissue before resistance (PRE) and post resistance 
(POST) to BRAF inhibitors. D. Relative expression of miR-17-5p normalized on spike-in control miR-39 in serum blood patients before 
therapy.
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then validated using a cohort of melanoma patients with 
BRAF mutations, treated with BRAF inhibitors and where 
PD-L1 expression in the metastatic lesions had been 
studied.
After stabilizing BiR and MiR cells, we observed 
that these variants had a more aggressive behavior 
compared to the S counterparts. Resistance induced 
expression of a panel of common genes linked to cell 
movement. Functionally, BiR and MiR cells were 
characterized by enhanced wound repair, which could 
be due to the up-regulation of molecules that play an 
essential role in melanoma metastasis, including integrin 
family members. However, a direct role of PD-L1 was 
shown after observing decreased wound healing in BiR 
or MiR cells where PD-L1 had been stably silenced by 
lentiviral infection. Interestingly, these cells also showed 
a marked down-regulation in the expression of CD56, 
which was proposed as a marker of desmoplastic and 
spindle-cell melanomas. Even if rare, this is a kind of 
melanoma with highly invasive properties. Even if future 
studies are needed to determine whether these tumors are 
constitutively PD-L1+, a recent report suggests that they 
are particularly sensitive to therapy with anti-PD1/PD-L1 
antibodies (abstract ASCO 2015).
The second result of this work concerns the 
identification of a post-transcriptional regulation of PD-
L1 levels, obtained through the miR-17-5p circuit. Our 
data indicate direct binding of this microRNA to the 3’-
UTR of PD-L1. Furthermore, transfection of miR-17-5p 
decreases expression of PD-L1, as well as aggressiveness 
of the tumor. The role of miR-17-5p cluster in cancer is 
matter of intense investigation. Loss of heterozigosity at 
the miR-17-5p locus, has been observed in association 
with progression of different kinds of solid tumors 
[34]. Furthermore, the miR-17-92 cluster is deleted in 
a significant proportion of human cancers, including 
20% of melanomas [35], suggesting an oncosuppressor 
role for this molecule. Our results would agree with this 
hypothesis, as BiR or MiR MM cell lines show a down-
regulation of this microRNA, as compared to sensitive 
cells. The molecular circuits responsible for miR-17-
5p modulation remain to be determined. At the light 
of recent data indicating loss of PTEN in aggressive 
melanoma, characterized by impaired immune responses, 
it is tempting to speculate that loss of PTEN may also 
be followed by loss of miR-17-5p, with the consequent 
lack of post-transcriptional regulation in PD-L1 and the 
described over-activation of the Wnt-β catenin Akt/PI3K 
pathways.
In the final part of the work, we exploited a large 
Italian cohort of MM patients that were treated with BRAFi 
or MEKi. From this analysis we draw three conclusions. 
The first is a confirmation that PD-L1 is an independent 
negative prognostic marker. The second is that, among 
PD-L1+ patients those lacking TIMC are characterized 
by the worst outcome, suggesting that constitutive PD-L1 
expression characterizes the most aggressive form of the 
disease. The third is that the acquisition of resistance to 
BRAFi induces expression of PD-L1 in the majority of 
cases. Lastly, comparison of miR-17-5p levels in plasma 
of patients with PD-L1+ MM biopsies show decreased 
plasmatic levels of miR-17-5p compared to patients with a 
PD-L1- lesion. If confirmed in larger cohorts, this finding 
suggests that miR-17-5p plasmatic levels may be used 
as inverse indicators of PD-L1 expression levels by the 
tumor. It will also be important to determine miR-17-5p 
levels in sequential samples and to correlate them with PD-
L1 expression levels in the corresponding biopsies.
MATERIALS AND METHODS
Melanoma cell lines
The A375, SKMEL5 and M14 BRAFV600E-mutated 
cell lines were originally obtained through the American 
Type Culture Collection (ATCC) and the BRAF 
mutational status confirmed by Sanger sequencing. Cells 
were cultured in RPMI-1640 + 10% fetal calf serum and 
100 IU/ml penicillin / streptomycin (all from Sigma, 
Milan, Italy, referred to as complete medium). BRAFi- 
and MEKi-resistant melanoma cells (indicated as BiR 
and MiR) were generated by treating cells with increasing 
concentrations of BRAFi (dabrafenib, GlaxoSmithKline, 
Brentford, UK) or MEKi (pimasertib, Merk Serono, 
Darmstadt, Germany), reaching the final concentration of 
1.6 μM in ≈12 weeks. Cells were thereafter maintained 
under these culture conditions [23, 36].
MTT viability assay
Cells were plated in complete medium and left 
overnight to attach to 96-well plates. BRAFi or MEKi 
were then added at the indicated concentrations for 72 
hours, before a 4-hour incubation with 10 μl of (3-(4,5-di
methylthiazolyl-2)-2,5 diphenyltetrazolium bromide, 
MTT, Thermo Scientific, Milan, Italy). The formazan 
crystals formed were dissolved in sodium dodecyl sulfate-
hydrochloride and absorbance was read at 570 nm using a 
microplate reader (Bio-Rad, Milan, Italy).
Flow-cytometry
Antibodies used for flow cytometry were: anti-PD-
L1-PE and -PE-Cy7, anti-CD24-APC, anti-CD56-PE, anti-
HLA-DR-PE-Cy7 (all from eBioscience, Milan, Italy), 
anti-integrin-α3 mAb (from Prof. G. Tarone, University of 
Turin, Italy). A secondary PE-conjugated goat anti-mouse 
Ig (Thermo Scientific, Milan, Italy) was used to highlight 
the binding of unlabeled antibodies.
Immunofluorescence data were acquired using a 
FACSCantoII cytofluorimeter and processed with DIVA 
v8.0 (BD Biosciences) and FlowJo Version 9.01 softwares 
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(TreeStar, Ashland, OR, USA), analyzing at least 10,000 
events per sample.
Western blot analysis
Cells were lysed, resolved by SDS-PAGE, and 
transferred to nitrocellulose filter membranes (Biorad, 
Milan) [27]. After blocking, membranes were incubated 
with: anti-PD-L1 (R&D Systems, Milan, Italy), -pSTAT3, 
-STAT3, -pERK1/2 and -ERK1/2 (all from Cell Signaling 
Technology, Danvers, MA). After incubation with 
horseradish peroxidase-conjugated secondary antibody 
(PerkinElmer, Milan, Italy), reaction was visualized with 
ECL using ImageQuant LAS4000 (GE Healthcare, Milan, 
Italy).
Confocal microscopy
Cells were cultured overnight on glass cover slips 
in 24-well plates before incubation with unlabeled anti-
PD-L1 antibody (eBioscience), followed by AlexaFluor-
488-conjugated goat anti-mouse IgG (Thermo Scientific). 
Phalloidin AlexaFluor-568-conjugated and DAPI (both 
from Thermo Scientific) were added after fixation (4% 
paraformaldehyde) and permeabilization (0.1% saponin). 
Slides were then analyzed using a TCS SP5 laser scanning 
confocal microscope equipped with 4 lasers and images 
were acquired with LAS AF Version Lite 2.4 software 
(Leica Microsystems, Wetzlar, Germany), as described 
[37]. Files were processed with Photoshop (Adobe 
Systems, San Jose, CA).
Wound healing assay
Melanoma cells were seeded in 6-well plates 
(5 × 105/well) and incubated in complete medium 
overnight. Cells were then treated with Mitomycin C 
(10 μg, 20 minutes, Sigma). Wounds were made with 
a 200 μl tip and the wells were washed several times 
to remove all non-adherent cells. Wound repair was 
documented at 24 hours using a DMI 3000 B optical 
microscope (Leica Microsystems), equipped with a DCF 
310 FX digital camera and LAS Version 3.8 software. 
Images were analyzed with MRI Wound Healing Tool of 
ImageJ software (NIH, USA). The percentage of repair 
was calculated as: [(area 
24 hours
/area
0 hours
) × 100%].
Chemotaxis and invasion assays
Migration and invasion were measured using 8 μM 
pore Boyden chambers (Corning, Corning, NY). Briefly, 
105 cells were plated in the upper chamber in serum free 
RPMI-1640 medium, while complete medium was added 
as a chemoattractant in the lower part. After 4 hours, cells 
in the upper part of the chamber were removed, while cells 
that had migrated to the lower surface of the filter stained 
with crystal violet (Sigma) and analyzed by bright-field 
microscopy. Migration index was calculated as: number 
of cells migrated in the presence of the chemoattractant / 
number of cells migrated without chemoattractant.
Invasion assays were performed after covering the 
upper part of the well with Matrigel (0.5 mg/ml, Corning). 
After 24 hours, cells that had not penetrated were wiped 
away, while cells that had invaded the lower surface of 
the filter were stained with crystal violet and examined 
by bright-field microscopy [38]. Invasion index was 
calculated as: number of cells penetrated in the presence of 
the chemoattractant / number of cells penetrated without 
chemoattractant.
Xenograft models
A375/S and A375/BiR cells (107) were injected 
subcutaneously in the presence of Matrigel into the right 
and left flanks, respectively, of 6- to 8-week-old male 
NOD/SCID mice. When tumors became palpable (≈ after 
two weeks), mice were treated with BRAFi (30 mg/kg) 
daily by gavage for 1 week (Tafinlar, Novartis, Basel, 
Switzerland). After treatment, animals were sacrificed 
and tumors measured. Lesions were then partly fixed 
and processed for histopathological studies and partly 
dissociated for cytofluorimetric analyses and cultures. Re-
cultured cells were tested to confirm resistance to BRAFi 
by the MTT assay.
Quantitative real-time PCR (qRT-PCR)
Total RNA (containing mRNAs and microRNAs) 
was extracted using miRNeasy kit (Qiagen, Milan, Italy) 
and converted to cDNA using the High Capacity cDNA 
Reverse Transcription kit (Thermo Scientific). qRT-PCR 
was performed using the 7900 HT Fast Real Time PCR 
system (SDS2.3 software) using commercially available 
primers (all from Thermo Scientific) and standardized over 
actin levels. Reactions were done in triplicate from the 
same cDNA reaction (technical replicates). Detection of 
microRNAs was performed by qRT-PCR for the specific 
hsa-miR and U6 snRNA (ID 001973, Thermo Scientific), 
as control for the cell lines. For normalization in blood 
sera from patients miR-39 from C. elegans [39] was added 
during the extraction of microRNAs. The comparative CT 
method was used to calculate the relative expression of the 
gene under analysis.
TargetScan 6.0 algorithm was used to identify 
predicted microRNA targets that bind 3’-UTR of PD-L1 
mRNA.
RNA sequencing (RNA-seq)
RNA-seq was performed as previously described 
[40], with few modifications. Briefly, the DNF-471 
Standard Sensitivity RNA Analysis Kit, run on Fragment 
Analyzer (both from Advanced Analytical, Ankeny IA) 
was used to check RNA quality. Libraries were prepared 
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from total RNA using TruSeq RNA Sample Preparation 
v2 according to the manufacturer's protocol (Illumina, 
San Diego, CA). Samples were sequenced on Illumina 
HiScanSQ platform. Sequencing reads were trimmed out 
of the low-quality bases with Fastx Toolkit (HannonLab, 
CHSL). Filtered sequences were mapped on hg19 genome 
assembly by using TopHat v2.0.6 and mRNA quantification 
was performed using Cuffdiff v2.0.2. For downstream 
analysis, genes with RPKM < 1 in all the samples were 
filtered out. Custom scripts on R software were used for 
clustering and heatmap analysis (https://www.r-project.
org/). Gene Ontology was analyzed by using Database 
for Annotation, Visualization and Integrated Discovery 
(DAVID) program (https://david.ncifcrf.gov/).
Transient transfections
Melanoma cell lines were transfected with pre-miR-
17-5p microRNA precursor molecules and microRNA 
negative control (Thermo Scientific) using HiPerFect 
Transfection Reagent (Qiagen). Expression of miRs or 
protein-coding genes overexpression/knockdown was 
monitored from 24 to 96 hours later by qRT-PCR.
Luciferase assays
Luciferase reporter vectors containing the partial PD-
L1 3’-UTR were generated following PCR amplification 
(forward primer: CAGGCAAGAATTGTGGCTGA, 
reverse primer: CCAAGTAACTTTCTCCACTGGGAT) 
of the 3’-UTR from human genomic DNA of PD-L1+ cells 
and cloning into the Firefly Luciferase reporter pMIR 
REPORT™ luciferase vector (Thermo Scientific). When 
indicated the 3’-UTR was mutagenized at the miR-17-
5p recognition site using the QuickChange Site-Directed 
Mutagenesis kit (Stratagene, Cedar Creek, TX) according 
to the manufacturer’s instructions (forward primer: GA
TGAAACATGAGACAAAAGGGATTATGAGGCTT 
ACAAATCCAACACCACAAGGA, reverse primer: TC
CTTGTGGTGTTGGATTTGTAAGCCTCATAATCCC 
TTTTGTCGCATGTTTCATC).
Cells (5 × 104) were then co-transfected with 50 
ng of the pMIR REPORT™ (Thermo Scientific) Firefly 
Luciferase constructs containing the 3’-UTRs of the 
specific microRNA potential target, 20 ng of pRL-TK 
Renilla Luciferase normalization control (Promega, 
Madison, WI) and 75 nM of the indicated pre-miR using 
Effectene (Qiagen). Lysates were collected 48 hours after 
transfection and Firefly and Renilla Luciferase activities 
were measured with a Dual-Luciferase Reporter System 
(Promega).
Preparation of lentiviruses
Lentiviral particles containing the genetic material 
for shPD-L1 (Origene, Rockville, MD) were generated 
according to the manufacture’s protocol.
Resistant cell lines were infected with shPD-L1 
lentiviral particles and expression of the molecule 
monitored 48 hours later by flow cytometry. To obtain 
stably PD-L1-silenced clones from A375 or SKMEL5 /
BiR or /MiR lines, infected cells were repeatedly sorted 
with a BD FACSAriaIII (BD Biosciences) by gating on 
GFP+/PD-L1-.
PD-L1 immunohistochemistry in human 
melanoma tissues
Cohort characteristics and detailed immuno-
histochemical protocols were previously described [31].
Statistical analyses
Continuous variables were compared by Mann-
Whitney test. The Wilcoxon matched-pairs signed rank 
test was used for paired variables.
For the clinical study, all melanoma patients 
satisfying eligibility criteria and treated with BRAFi were 
considered for analysis. Overall response rate (ORR) 
was defined as the proportion of patients with complete 
response or partial response, according to RECIST, v1.1 
[41]. Progression free survival (PFS) was defined as the 
time from the beginning of BRAFi to first appearance of 
progressive disease or death for any cause; patients known 
to be alive and without progressive disease at the time of 
analysis were censored at their last available follow-up 
assessment. Overall survival (OS) was defined as the time 
from the beginning of BRAFi to the date of death from 
any cause or the date of the last follow-up. Survival curves 
were estimated with the Kaplan-Meier method. PFS and 
OS were analyzed by means of Cox regression model and 
results were expressed as hazard ratios (HR) with their 
95% confidence intervals (95% CI) ORR was analyzed 
by means of logistic regression models and results were 
expressed as odds ratios (OR) with their 95 %CI.
Statistical analyses were performed using 
SAS software, version 9.2 (SAS Institute, Cary, NC) 
and GraphPad version 6 (GraphPad Software Inc, 
La Jolla, CA).
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